世界の末梢動脈疾患（PAD）治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4519 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、末梢動脈疾患（PAD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗血小板薬、二重抗血小板療法薬、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・末梢動脈疾患（PAD）治療薬の市場動向 ・企業の競争状況、市場シェア ・末梢動脈疾患（PAD）治療薬の種類別市場規模（抗血小板薬、二重抗血小板療法薬、その他） ・末梢動脈疾患（PAD）治療薬の用途別市場規模（病院、診療所、その他） ・末梢動脈疾患（PAD）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・末梢動脈疾患（PAD）治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・末梢動脈疾患（PAD）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・末梢動脈疾患（PAD）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・末梢動脈疾患（PAD）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca Plc. (UK)、Bayer HealthCare Pharmaceuticals (Germany)、Bristol-Myers Squibb Company (US)、Merck & Co., Inc. (US)、Proteon Therapeutics, Inc. (US)、Sanofi S.A. (France)、Symic Bio, Inc. (US)、TheraVasc Inc. (US)、AnGes MG, Inc. (Japan)、Athersys, Inc. (US)、Betagenon AB (Sweden)、miRagen Therapeutics, Inc. (US)、Multi Gene Vascular Systems Ltd (Israel)、ViroMed Co. Ltd. (Korea)） ・結論

Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.

Market Analysis and Insights: Global Peripheral Arterial Disease (PAD) Therapeutics Market
The global Peripheral Arterial Disease (PAD) Therapeutics market size is projected to reach US$ 4249.9 million by 2026, from US$ 2940 million in 2019, at a CAGR of 5.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Peripheral Arterial Disease (PAD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Peripheral Arterial Disease (PAD) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Peripheral Arterial Disease (PAD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Peripheral Arterial Disease (PAD) Therapeutics market.

Global Peripheral Arterial Disease (PAD) Therapeutics Scope and Market Size
Peripheral Arterial Disease (PAD) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Peripheral Arterial Disease (PAD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
miRagen Therapeutics, Inc. (US)

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Anti-Platelet Drugs
1.2.3 Dual Antiplatelet Therapy Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Perspective (2016-2027)
2.2 Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Regions
2.2.1 Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Peripheral Arterial Disease (PAD) Therapeutics Industry Dynamic
2.3.1 Peripheral Arterial Disease (PAD) Therapeutics Market Trends
2.3.2 Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
2.3.3 Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
2.3.4 Peripheral Arterial Disease (PAD) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue
3.1.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
3.4 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio
3.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2020
3.5 Peripheral Arterial Disease (PAD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
3.7 Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Type
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Application
5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2016-2027)
6.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
6.2.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2027)
6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application
6.3.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2027)
6.4 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
6.4.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2016-2027)
7.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
7.2.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application
7.3.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
7.4.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2016-2027)
9.2 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
9.2.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application
9.3.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
9.4.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca Plc. (UK)
11.1.1 AstraZeneca Plc. (UK) Company Details
11.1.2 AstraZeneca Plc. (UK) Business Overview
11.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.1.5 AstraZeneca Plc. (UK) Recent Development
11.2 Bayer HealthCare Pharmaceuticals (Germany)
11.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Details
11.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
11.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
11.3 Bristol-Myers Squibb Company (US)
11.3.1 Bristol-Myers Squibb Company (US) Company Details
11.3.2 Bristol-Myers Squibb Company (US) Business Overview
11.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.3.5 Bristol-Myers Squibb Company (US) Recent Development
11.4 Merck & Co., Inc. (US)
11.4.1 Merck & Co., Inc. (US) Company Details
11.4.2 Merck & Co., Inc. (US) Business Overview
11.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.4.5 Merck & Co., Inc. (US) Recent Development
11.5 Proteon Therapeutics, Inc. (US)
11.5.1 Proteon Therapeutics, Inc. (US) Company Details
11.5.2 Proteon Therapeutics, Inc. (US) Business Overview
11.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.5.5 Proteon Therapeutics, Inc. (US) Recent Development
11.6 Sanofi S.A. (France)
11.6.1 Sanofi S.A. (France) Company Details
11.6.2 Sanofi S.A. (France) Business Overview
11.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.6.5 Sanofi S.A. (France) Recent Development
11.7 Symic Bio, Inc. (US)
11.7.1 Symic Bio, Inc. (US) Company Details
11.7.2 Symic Bio, Inc. (US) Business Overview
11.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.7.5 Symic Bio, Inc. (US) Recent Development
11.8 TheraVasc Inc. (US)
11.8.1 TheraVasc Inc. (US) Company Details
11.8.2 TheraVasc Inc. (US) Business Overview
11.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.8.5 TheraVasc Inc. (US) Recent Development
11.9 AnGes MG, Inc. (Japan)
11.9.1 AnGes MG, Inc. (Japan) Company Details
11.9.2 AnGes MG, Inc. (Japan) Business Overview
11.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.9.5 AnGes MG, Inc. (Japan) Recent Development
11.10 Athersys, Inc. (US)
11.10.1 Athersys, Inc. (US) Company Details
11.10.2 Athersys, Inc. (US) Business Overview
11.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.10.5 Athersys, Inc. (US) Recent Development
11.11 Betagenon AB (Sweden)
11.11.1 Betagenon AB (Sweden) Company Details
11.11.2 Betagenon AB (Sweden) Business Overview
11.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.11.4 Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.11.5 Betagenon AB (Sweden) Recent Development
11.12 miRagen Therapeutics, Inc. (US)
11.12.1 miRagen Therapeutics, Inc. (US) Company Details
11.12.2 miRagen Therapeutics, Inc. (US) Business Overview
11.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.12.4 miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.12.5 miRagen Therapeutics, Inc. (US) Recent Development
11.13 Multi Gene Vascular Systems Ltd (Israel)
11.13.1 Multi Gene Vascular Systems Ltd (Israel) Company Details
11.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview
11.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.13.4 Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Development
11.14 ViroMed Co. Ltd. (Korea)
11.14.1 ViroMed Co. Ltd. (Korea) Company Details
11.14.2 ViroMed Co. Ltd. (Korea) Business Overview
11.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.14.4 ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
11.14.5 ViroMed Co. Ltd. (Korea) Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Anti-Platelet Drugs
Table 3. Key Players of Dual Antiplatelet Therapy Drugs
Table 4. Key Players of Others
Table 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions (2022-2027)
Table 11. Peripheral Arterial Disease (PAD) Therapeutics Market Trends
Table 12. Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
Table 13. Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
Table 14. Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
Table 15. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2020)
Table 18. Ranking of Global Top Peripheral Arterial Disease (PAD) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
Table 22. Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. AstraZeneca Plc. (UK) Company Details
Table 63. AstraZeneca Plc. (UK) Business Overview
Table 64. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 65. AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 66. AstraZeneca Plc. (UK) Recent Development
Table 67. Bayer HealthCare Pharmaceuticals (Germany) Company Details
Table 68. Bayer HealthCare Pharmaceuticals (Germany) Business Overview
Table 69. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 70. Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Bayer HealthCare Pharmaceuticals (Germany) Recent Development
Table 72. Bristol-Myers Squibb Company (US) Company Details
Table 73. Bristol-Myers Squibb Company (US) Business Overview
Table 74. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 75. Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Bristol-Myers Squibb Company (US) Recent Development
Table 77. Merck & Co., Inc. (US) Company Details
Table 78. Merck & Co., Inc. (US) Business Overview
Table 79. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 80. Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Merck & Co., Inc. (US) Recent Development
Table 82. Proteon Therapeutics, Inc. (US) Company Details
Table 83. Proteon Therapeutics, Inc. (US) Business Overview
Table 84. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 85. Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Proteon Therapeutics, Inc. (US) Recent Development
Table 87. Sanofi S.A. (France) Company Details
Table 88. Sanofi S.A. (France) Business Overview
Table 89. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 90. Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Sanofi S.A. (France) Recent Development
Table 92. Symic Bio, Inc. (US) Company Details
Table 93. Symic Bio, Inc. (US) Business Overview
Table 94. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 95. Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Symic Bio, Inc. (US) Recent Development
Table 97. TheraVasc Inc. (US) Company Details
Table 98. TheraVasc Inc. (US) Business Overview
Table 99. TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 100. TheraVasc Inc. (US) Recent Development
Table 101. AnGes MG, Inc. (Japan) Company Details
Table 102. AnGes MG, Inc. (Japan) Business Overview
Table 103. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 104. AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 105. AnGes MG, Inc. (Japan) Recent Development
Table 106. Athersys, Inc. (US) Company Details
Table 107. Athersys, Inc. (US) Business Overview
Table 108. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 109. Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 110. Athersys, Inc. (US) Recent Development
Table 111. Betagenon AB (Sweden) Company Details
Table 112. Betagenon AB (Sweden) Business Overview
Table 113. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 114. Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 115. Betagenon AB (Sweden) Recent Development
Table 116. miRagen Therapeutics, Inc. (US) Company Details
Table 117. miRagen Therapeutics, Inc. (US) Business Overview
Table 118. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 119. miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 120. miRagen Therapeutics, Inc. (US) Recent Development
Table 121. Multi Gene Vascular Systems Ltd (Israel) Company Details
Table 122. Multi Gene Vascular Systems Ltd (Israel) Business Overview
Table 123. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 124. Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 125. Multi Gene Vascular Systems Ltd (Israel) Recent Development
Table 126. ViroMed Co. Ltd. (Korea) Company Details
Table 127. ViroMed Co. Ltd. (Korea) Business Overview
Table 128. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 129. ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021) & (US$ Million)
Table 130. ViroMed Co. Ltd. (Korea) Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Anti-Platelet Drugs Features
Figure 3. Dual Antiplatelet Therapy Drugs Features
Figure 4. Others Features
Figure 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Peripheral Arterial Disease (PAD) Therapeutics Report Years Considered
Figure 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players in 2020
Figure 15. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2020
Figure 17. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2016-2027)
Figure 39. China Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. AstraZeneca Plc. (UK) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 59. Bayer HealthCare Pharmaceuticals (Germany) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 60. Bristol-Myers Squibb Company (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 61. Merck & Co., Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 62. Proteon Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 63. Sanofi S.A. (France) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 64. Symic Bio, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 65. TheraVasc Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 66. AnGes MG, Inc. (Japan) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 67. Athersys, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 68. Betagenon AB (Sweden) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 69. miRagen Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 70. Multi Gene Vascular Systems Ltd (Israel) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 71. ViroMed Co. Ltd. (Korea) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

---